Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Myriad Genetics to post earnings of $0.03 per share and revenue of $210.35 million for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Myriad Genetics Stock Performance

Shares of Myriad Genetics stock traded down $0.79 on Friday, hitting $14.19. The stock had a trading volume of 988,019 shares, compared to its average volume of 1,091,045. Myriad Genetics has a twelve month low of $12.04 and a twelve month high of $29.30. The business's 50 day moving average is $13.45 and its two-hundred day moving average is $19.57. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -10.92 and a beta of 1.88.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. UBS Group assumed coverage on Myriad Genetics in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $18.00 target price on the stock. Piper Sandler decreased their target price on Myriad Genetics from $24.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, January 30th. StockNews.com downgraded Myriad Genetics from a "buy" rating to a "hold" rating in a research report on Thursday. Stephens reaffirmed an "equal weight" rating and issued a $20.00 target price on shares of Myriad Genetics in a research report on Thursday, January 16th. Finally, Leerink Partnrs cut Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Myriad Genetics has a consensus rating of "Hold" and a consensus price target of $22.54.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.